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OBJECTIVES This study was designed to determine the stage of myocardial dysfunction at which an
upregulation of the Na1/Ca21exchanger (EXCH) transcription takes place.
BACKGROUND Because EXCH is an important regulator of intracellular calcium homeostasis, alterations in
EXCH expression may occur before the onset of end-stage heart failure (HF) to maintain
normal intracellular Ca21 concentrations. We analyzed whether the EXCH transcription
level is correlated to the degree of myocardial dysfunction and whether it can be a suitable
molecular marker to define the transition to myocardial decompensation early on.
METHODS By quantitative polymerase chain reaction technique, the level of EXCH transcription was
analyzed in myocardial biopsies from 40 patients with various degrees of myocardial
dysfunction due to valvular heart disease (VHD; n 5 22) or dilated cardiomyopathy (DCM;
n 5 18). Additionally, biopsies from 7 individuals with excluded heart disease and explanted
heart tissue from 13 patients with end-stage HF were investigated.
RESULTS The level of EXCH transcription of controls (2.6 6 1.2 attomoles [amol]/ng total RNA) did
not differ from that of patients with DCM (2.3 6 1.5 amol/ng) or VHD (2.1 6 1.5 amol/ng).
No alteration in the EXCH transcription was found in VHD and DCM patients with respect
to the severity of myocardial dysfunction. However, patients with end-stage HF showed a
four-fold increase in EXCH transcription, amounting to 8.9 6 1.9 amol/ng (p , 0.05).
CONCLUSIONS The upregulation in EXCH transcription either occurs very late in human heart failure or is
a phenomenon of heart transplantation in end-stage HF. Consequently, myocardial EXCH
transcription cannot be used as a marker for early myocardial decompensation. (J Am Coll
Cardiol 2000;36:233–41) © 2000 by the American College of Cardiology
An upregulation of the sarcolemmal Na1/Ca21 exchanger
(EXCH), an important regulator of the intracellular calcium
concentration in both mRNA and protein levels, has been
demonstrated in end-stage heart failure (HF) (1,2). The
electrogenic exchange of one Ca21 for three Na1 ions across
the sarcolemmal membrane by the EXCH maintains low
diastolic cytosolic Ca21 levels and enables diastolic relax-
ation to take place (3,4). In addition, the EXCH improves
cardiac contractility by increasing the systolic influx of Ca21
ions into the cell (2,5,6). An upregulation of the EXCH
may help to compensate abnormally high intracellular Ca21
concentrations that contribute to the systolic and diastolic
functional impairment in the failing heart (7–9).
As diastolic and systolic functions are disturbed long
before HF manifests itself, we investigated the stage of
myocardial dysfunction at which the EXCH transcription
alters, and whether this alteration in the EXCH is a suitable
molecular marker for defining the prognostically important
transition from adequate to inadequate myocardial adapta-
tion due to chronic pressure and/or volume overload (10–
14).
To this end, and for the first time ever, the EXCH
transcription level was determined in endomyocardial biop-
sies from patients with mild to severe myocardial dysfunc-
tion and was compared with that measured in hearts
explanted from patients with end-stage HF.
METHODS
Patients
Forty patients (age range 31–85 years, mean 57 6 13 years;
27 men, 13 women) with chronic pressure overload (aortic
stenosis [AS], 11 patients), volume overload (aortic regur-
gitation [AR], 5 patients; primary mitral regurgitation
[MR], 6 patients) or dilated cardiomyopathy (18 patients)
were examined. All patients underwent diagnostic right and
left heart catheterization including coronary angiography.
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Significant (.50%) coronary artery disease was excluded in
all patients. During right heart catheterization, small biop-
sies were taken from the interventricular septum, immedi-
ately frozen in liquid nitrogen and stored at 280°C. The
EXCH expression has been shown to be the same in the
interventricular septum and the right and left ventricles in
hearts explanted from patients with end-stage HF (15).
Biopsies were screened to exclude the presence of myocar-
ditis according to the Dallas classification (16). The study
was approved by the ethics committee of the Free University
of Berlin, Germany.
The clinical and hemodynamic characteristics of the
patients enrolled in the study are listed in Tables 1 and 2.
The severity of aortic valve obstruction was graded accord-
ing to the transvalvular pressure loss (PLaorta), the mean
transaortic pressure gradient (dp) and effective stroke vol-
ume coefficient, which was determined from the simulta-
neous records of the left ventricular (transseptal technique)
and aortic pressure curves. Effective left ventricular stroke
volume was determined by the thermodilution method.
Hemodynamically relevant AS was defined as PLaorta $
1 mm Hg per ml stroke volume (14). Aortic regurgitation
and MR were estimated using the transvalvular regurgitant
fraction (RF), which is the difference between total (mea-
sured angiographically) and effective left ventricular stroke
volume (measured by thermodilution technique). Regurgi-
tant fractions of .30% were considered hemodynamically
relevant (13) (Table 1).
In addition to valvular patients, endomyocardial samples
were taken from the right ventricular septum of 13 ex-
planted hearts (Table 3) failing because of dilated cardio-
myopathy (DCM; n 5 2) or ischemic cardiomyopathy
(ICM; n 5 11). Endomyocardial samples from two healthy
donors and from five individuals without myocardial dys-
function, who underwent cardiac catheterization and myo-
cardial biopsies to exclude coronary artery disease and
myocarditis, served as controls.
Assessment of Ventricular Function
Left ventricular ejection fraction (EF) and total stroke
volume were determined by cineangiography using the
analytic calibration method (17,18). Cardiac index (CI) was
calculated as the average of five thermodilution measure-
ments. Hemodynamic data are given in Tables 1 and 2. All
patients had transthoracic echocardiography including mea-
surement of left ventricular end-diastolic (LVEDD) and
end-systolic (LVESD) dimensions, fractional shortening
(FS), end-diastolic left ventricular posterior wall thickness
(LVPW) and maximal systolic meridional wall stress (ws)
(g/cm2) (Tables 1 and 2). Wall stress was determined
according to the Laplace law. Left ventricular radius
(LVEDD/2), LVPW and left ventricular peak systolic
pressure (LVPRsyst), measured during catheterization, were
used to calculate left ventricular wall stress according to the
following equation (10):
ws 5
~LVEDD/2! 3 ~0.334 3 LVPRsyst!
LVPW
g/cm2
Quantitative Polymerase Chain Reaction
The competitive quantitative polymerase chain reaction
(q-PCR) was employed to determine the EXCH messenger
ribonucleic acid (mRNA) amount in the endomyocardial
specimens from the patients described. An internal RNA
standard was used, simultaneously reversely transcribed with
the target RNA and competitively amplified in the PCR.
Construction of the competitor. A bluescript vector,
containing 1.3 kb of the coding and 0.2 kb of the noncoding
sequence from guinea pig EXCH complementary deoxyri-
bonucleic acid (cDNA), was used for the synthesis of
competitor complementary RNA. An 82-bp fragment was
released from the coding region by digestion with Bcll and
Hpal. After religation 10 mg plasmid was linearized with
Xhol according to the instructions of the manufacturer
(Boehringer Mannheim). Transcription was performed in a
reaction mixture containing 1 mg plasmid, 5 ml 53 tran-
scription puffer, 5 mmol/liter DTT, 10 U RNAsin-
Inhibitor (Boehringer Mannheim) and 4 mmol/liter each of
rNTP and 100 U T3-polymerase (Stratagene) at 37°C for
1 h. The transcription mixture was subjected to a 1%
low-melting gel electrophoresis. cRNA was extracted with
phenol/chloroform and was precipitated with 0.1 vol%
sodium acetate pH 5.2 and 2.5 vol% ethanol at 280°C
overnight. The RNA was stabilized with tRNA (100 ng
tRNA/ml cRNA). The purity of the standard was proved by
PCR using nontranscribed standard RNA, which produced
no detectable signal.
Quantitative PCR. Total RNA was extracted from the
endomyocardial biopsies using the LiCl method (19). The
conditions of the reverse transcription and the PCR were
optimized, especially in view of the cycles, the amount of
isolated total RNA and standard cRNA (data not shown).
The following conditions were employed: equal amounts of
total RNA (7.5 ng) isolated from the endomyocardial
specimens were mixed with increasing amounts of compet-
itor (3.5, 7, 14, 28, 56, 112, 224, and 448 attomoles [amol])
in a reverse transcription (RT) mixture of 12.5 ml, contain-
Abbreviations and Acronyms
AR 5 aortic regurgitation
AS 5 aortic stenosis
CI 5 cardiac index
DCM 5 dilated cardiomyopathy
EF 5 ejection fraction
EXCH 5 Na1/Ca21 exchanger
ICM 5 ischemic cardiomyopathy
MR 5 mitral regurgitation
NYHA 5 New York Heart Association
PLaorta 5 transaortic pressure loss
RFaorta 5 transaortic regurgitation
RFmitral 5 transmitral regurgitation
VAD 5 ventricular assist device
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ing 2.5 ml 5 3 first strand buffer (GIBCO, Karlsruhe,
Germany), 5 U RNAse Inhibitor (Boehringer Mannheim),
0.4 mmol/liter of dNTP mix (Boehringer Mannheim), 8 ng
random primer, 8 mmol/liter DTT and 200 U MMLV-
Reverse transcriptase (GIBCO).
Sense and antisense primers (59: 59-AAT GAG CTT
GGT TTC ACA-39 and 39: 59-CCG CCG ATA CAG
CAG CAC-39) were chosen to lie in homologous regions of
the human (20) and guinea pig (21) cDNA sequences.
Competitive PCRs were carried out in a 25-ml reaction
mixture containing 10 mmol/liter Tris-HCl, pH 8.3; 50
mmol/liter KCl; 1.5 mmol/liter MgCl2; 200 mmol/liter of
each dNTPs; 0.4 mmol/liter of each primer; 5 ml RT
mixture and 0.63 U of Taq polymerase (Cetus Perkin
Elmer, Weiterstadt, Germany). The denaturation, anneal-
ing and extension conditions for the amplification were 45 s
at 94°C, 45 s at 60°C and 90 s at 72°C. Thirty amplification
cycles were performed with a thermal cycler (Biozyme).
Polymerase chain reaction products were subjected to aga-
rose gel electrophoresis and stained with ethidium bromide.
Gels were scanned by a computer-based video system
(Polaroid, Offenbach, Germany). The intensity of the
ethidium–bromide-stained bands of the target and the
competitor RNA were evaluated by a computer-based
imaging system (NIH image). To correct for differences in
the size of the target (861 bp) and the competitor (778 bp)
PCR products, the band densities of the respective compet-
itors were multiplied by the specific factor of 1.11. The
target/competitor ratio was plotted against the amount of
competitor in a log scale. The linear regression was calcu-
lated. The amount of competitor corresponding to the log
ratio value of 0 is equivalent to the amount of total
EXCH-specific RNA in the specimens. The level of EXCH
transcription was expressed as amol/ng of total RNA.
Statistical analysis. All data are given as mean 6 SD. For
statistical analysis nonparametric tests were used; for com-
parisons of more than two groups the Kruskal Wallis test
was applied for testing the global hypothesis. In case of a
significant result, the nonparametric Dunn’s test was then
used to assess the two-by-two differences. The test of Dunn
is based on the comparison in pairs of the mean ranks of the
groups. All analyses were performed using SPSS 8.0 soft-
ware, except for the Dunn’s test (SAS 6.13, Cary, North
Carolina).
The p values are given in the following classes: ,0.01 and
,0.05. A p value of ,0.05 was considered significant.
RESULTS
This study was designed to clarify whether changes in
cardiac function are associated with an altered transcription
of the sarcolemmal EXCH in patients with valvular heart
disease or DCM. To determine the EXCH mRNA copy
number in small endomyocardial biopsy samples, the quan-
titative PCR technique was employed, using an internal
RNA standard as a competitor (Fig. 1).
The EXCH mRNA level amounted to an average of
2.6 6 1.2 amol/ng total RNA in the control group. A
fourfold increase (8.9 6 1.9 amol/ng) was found in hearts
explanted from patients with end-stage HF due to ischemic
or DCM, whereas no differences were seen in patients with
AS (1.8 6 1.4 amol/ng), AR/MR (2.0 6 1.5 amol/ng) or
DCM (2.3 6 1.5 amol/ng) (Fig. 2).
No significant changes in EXCH mRNA amount were
found in the group of patients with normal to mildly
impaired (EF . 50%) left ventricular EF, with an EF of
30% to 49% or with an EF , 30% (Fig. 3). Similar results
were obtained when EXCH amount was correlated to CI,
as patients with normal CI (CI . 3.5 liters/min/m2),
reduced CI (CI 2.4 –3.5 liters/min/m2) or very low CI
(CI , 2.4 liters/min/m2) had similar EXCH amounts of
2.0 6 1.6, 2.0 6 1.5 or 2.5 6 1.3 amol/ng total RNA.
There was no correlation to other invasively measured
hemodynamic parameters and echocardiographic data,
nor was there a correlation to the hemodynamic severity
of valvular stenosis or valvular regurgitations (Tables 1
and 2).
Not even patients with severe HF (New York Heart
Association [NYHA] grade IV) and a critical hemodynamic
condition showed an increase in EXCH transcription,
which was found only in tissue from explanted hearts. The
EXCH mRNA tended to be lower in patients with heart
valve disease and NYHA class I or II than in those with
heart valve disease and NYHA class III or IV which was not
seen in patients with dilated cardiomyopathy (Fig. 4).
Systolic wall stress, a parameter indicating the state of
myocardial adaptation to increased workload, did not induce
an increase in the EXCH mRNA level (Fig. 5).
Table 3. Clinical and Hemodynamic Characteristics of Patients
Undergoing Heart Transplantation Because of End-Stage HF
Caused by Ischemia (End-Stage ICM) or Dilated
Cardiomyopathy (End-Stage DCM)
Clinical Data Angiocardiography
Patient
(n)
Diagnosis Gender Age
(yr)
EF
Angio
(%)
CI
(l/min/m2)
1 end-stage-ICM m 61 20 1.4
2 end-stage-ICM m 62 22 1.6
3 end-stage ICM m 61 13 1.7
4 end-stage-ICM m 52 15 1.9
5 end-stage-ICM m 52 13 2
6 end-stage-ICM m 68 11 1.3
7 end-stage-ICM m 66 11 1.6
8 end-stage ICM m 59 16 2.1
9 end-stage-ICM m 68 15 1.3
10 end-stage-ICM m 63 22 2
11 end-stage-ICM m 50 14 1.4
12 end-stage-DCM m 47 13 1.3
13 end-stage-DCM m 55 20 1.7
EF 5 ejection fraction; CI 5 cardiac index.
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DISCUSSION
Transcription and translation of EXCH is known to be
upregulated in myocardium of failing hearts. This may be
related to changes in calcium homeostasis. The stage of
cardiac dysfunction at which upregulation occurs is un-
known so far. We therefore examined the EXCH mRNA
level in endomyocardial biopsies from patients with mildly,
moderately and severely impaired left ventricular function,
employing the quantitative PCR technique.
EXCH and calcium homeostasis. Consistent with earlier
findings (1,2), we found a significant increase in the EXCH
mRNA amount in explanted human myocardium from
patients with end-stage HF. However, we did not see any
alterations of EXCH in endomyocardial biopsies from
patients with heart failure of varying severity. These findings
indicate that the EXCH mRNA level does not change until
the myocardium has been finally damaged.
In severe, but not end-stage, HF the intracellular calcium
homeostasis seems to be maintained without alteration of
the EXCH expression (22). It is likely that the upregulation
of the EXCH observed in end-stage HF is necessary to
compensate intracellular calcium overload by increasing the
calcium efflux across the sarcolemmal membrane (23).
Schillinger et al. (24) reported that a subset of patients with
Figure 1. Total EXCH mRNA quantification by competitive PCR. A constant amount of total RNA (7.5 ng), isolated from an endomyocardial biopsy
from a patient suffering from DCM, was mixed with a decreasing amount of competitor cRNA, reverse transcribed and amplified by PCR.
Figure 2. Plots showing a significant difference (p , 0.05) between the
Na1/Ca21 exchanger mRNA levels of explanted hearts (expl) from
patients with end-stage heart failure and those found in endomyocardial
tissues of controls (c), of patients with aortic stenosis (AS), aortic or mitral
regurgitation (AR/MR), and of dilated cardiomyopathy (DCM).
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end-stage HF had higher levels of EXCH. This study
divided the patients into groups with either predominant
systolic or predominant diastolic alteration of the force
development in isolated muscle strips. Patients with systolic
dysfunction showed only slightly increased protein levels of
EXCH, whereas EXCH levels doubled in patients with
diastolic dysfunction. In the latter group, an inverse rela-
tionship between EXCH levels and the severity of diastolic
dysfunction was observed, pinpointing the importance of
EXCH for diastolic function.
EXCH upregulation. In our study, upregulation of the
myocardial EXCH was found to occur only after manifes-
tation of end-stage HF. Whether this upregulation of
EXCH occurred shortly before or during heart transplan-
tation is not known. Dipla et al. (25) observed, in favor for
EXCH upregulation before heart transplantation, alter-
ations in calcium homeostasis just before heart transplanta-
tion was performed. They showed that if patients were put
on a ventricular assist device (VAD) before transplantation,
contractility, relaxation and catecholamine responsiveness of
myocytes isolated from explanted hearts improved, because
VAD therapy resulted in higher Ca21 transportation rates.
This indicates an interaction between central hemodynam-
ics and calcium homeostasis. Whether alterations in the
EXCH expression were involved in the improvement of
calcium transportation rates and of myocardial function
remains speculative, although an upregulation of the EXCH
expression has been shown to be related to the severity of
diastolic dysfunction in failing human hearts (24,26).
Potential mechanisms of EXCH upregulation. The rise
in the EXCH amount may be due to an extremely decel-
erated relaxation, a reduced response to beta-adrenergic
stimulation, decreased force production (25,27) or biochem-
ical changes (acidosis and ATP depletion in endomyocardial
Figure 3. No significant changes in the Na1/Ca21 exchanger mRNA
transcription level were obtained within patients with chronic heart failure
(CHF) irrespective of left ventricular ejection fractions (EFs): EF $ 50%,
EF 5 30%–49% or EF , 30%. But a significant (p , 0.01) difference in
EXCH transcription was found between patients with severe CHF (EF ,
30%) and explanted hearts (expl), although EF was reduced similarly.
Figure 4. Plots showing a significant difference (p , 0.01) in the EXCH transcription level, even between CHF in NYHA IV and expl, although the clinical
situation was similar. Otherwise, a nonsignificant tendency toward lower EXCH mRNA levels was found in NYHA I/II compared with NYHA III/IV
for VHD, not seen in DCM.
Figure 5. No significant elevation in EXCH transcription level in CHF
according to systolic wall stress, a parameter indicating the state of
myocardial adaptation to increased workload, is demonstrated.
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ischemia [28], increased levels of circulating cytokines [29]
or neurohumoral activation [28,30]) frequently observed in
HF.
Otherwise, upregulation of the EXCH mRNA amount is
likely to be a phenomenon induced by heart transplantation
or perioperative procedures/medications, especially in pa-
tients with severely damaged heart tissue (31,32). An
alteration in the EXCH expression was shown to occur
within 1 to 2 h of acute pressure overload (33), pharmaco-
logically induced increase of Na1 influx (33) or acute
ischemia induced in animal models. For example, a signif-
icant upregulation of the EXCH expression was seen after
adrenergic stimulation with phenylephrine in ventricular
cardiocytes of rats, but not if the alpha-receptors had been
blocked with prazosin (34). These data demonstrate that, in
rats, alpha-adrenergic stimulation induces an increase in
EXCH mRNA within 1 h and an increase in protein levels
within 24 h. However, in patients with end-stage HF,
catecholamines do not seem to influence the upregulation of
EXCH transcripts, as elevated EXCH levels were docu-
mented even when all patients who had received cat-
echolamines preoperatively were excluded (2).
Volatile anesthetics such as halothane are known to
influence EXCH by decreasing the activity of the ex-
changer, which in turn may induce an elevation of EXCH
transcription to compensate for the loss of EXCH activity
(35,36).
Myocardial adaptation. Our data show that alterations in
EXCH transcription do not parallel myocardial dysfunc-
tion, but occur only in conjunction with end-stage HF.
Therefore, EXCH expression is not an early marker for
inadequate myocardial adaptation to chronic pressure
and/or volume overload (37,38), and timing of surgical
intervention may not be directed by this parameter (39,40).
Study limitations. In this study, the EXCH mRNA
levels, but not the EXCH protein levels, were measured in
endomyocardial tissue from patients with various degrees of
HF. The limited biopsy material forced us to neglect this
parameter. However, this parameter is not essential for the
assessment of EXCH alterations in patients with myocar-
dial dysfunction, as other groups have shown that an
increase in mRNA level is always accompanied by an
increase in EXCH protein level.
Conclusion. Our data indicate that the EXCH transcrip-
tion level is upregulated in explanted human hearts with
end-stage HF, but not in myocardial biopsies from patients
with moderate to severe HF. Upregulation of EXCH
expression either occurs very late in the natural history of
HF as an indication of irreversible myocardial damage or is
a phenomenon of hemodynamic, autocrine, endocrine, isch-
emic and/or drug-induced changes during heart transplan-
tation.
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